164 related articles for article (PubMed ID: 23100146)
1. Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients.
Carcamo WC; Ceribelli A; Calise SJ; Krueger C; Liu C; Daves M; Villalta D; Bizzaro N; Satoh M; Chan EK
J Clin Immunol; 2013 Feb; 33(2):420-6. PubMed ID: 23100146
[TBL] [Abstract][Full Text] [Related]
2. Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.
Keppeke GD; Satoh M; Ferraz ML; Chan EK; Andrade LE
Immunol Res; 2014 Oct; 60(1):38-49. PubMed ID: 24845459
[TBL] [Abstract][Full Text] [Related]
3. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.
Keppeke GD; Calise SJ; Chan EK; Andrade LE
World J Gastroenterol; 2016 Feb; 22(6):1966-74. PubMed ID: 26877604
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Covini G; Carcamo WC; Bredi E; von Mühlen CA; Colombo M; Chan EK
Antivir Ther; 2012; 17(5):805-11. PubMed ID: 22293655
[TBL] [Abstract][Full Text] [Related]
5. Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.
Stinton LM; Myers RP; Coffin CS; Fritzler MJ
BMC Gastroenterol; 2013 Mar; 13():50. PubMed ID: 23506439
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.
Dammermann W; Polywka S; Dettmann I; Mindorf S; Komorowski L; Wehmeyer M; Schulze Zur Wiesch J; Stöcker W; Lüth S
Med Microbiol Immunol; 2017 Oct; 206(5):379-382. PubMed ID: 28815296
[TBL] [Abstract][Full Text] [Related]
7. Association of Autoantibody to Rods and Rings with Hepatitis C Outcome and Viral Load.
Dhaouadi T; Abdellatif J; Jallouli M; Mejdoubi M; Sfar I; Mouelhi L; Aouini S; Ben Abdallah T; Gorgi Y
Viral Immunol; 2019 Jun; 32(5):214-220. PubMed ID: 31081724
[TBL] [Abstract][Full Text] [Related]
8. Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment.
da Silva Sacerdote AB; Filgueira NA; de Barros Barreto S; Batista AD; Lopes EP
Immunol Res; 2018 Oct; 66(5):605-610. PubMed ID: 30220012
[TBL] [Abstract][Full Text] [Related]
9. Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against "rings and rods"-associated inosine-5'-monophosphate dehydrogenase 2 in viral hepatitis C.
Probst C; Radzimski C; Blöcker IM; Teegen B; Bogdanos DP; Stöcker W; Komorowski L
Clin Chim Acta; 2013 Mar; 418():91-6. PubMed ID: 23333419
[TBL] [Abstract][Full Text] [Related]
10. Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients.
Novembrino C; Aghemo A; Ferraris Fusarini C; Maiavacca R; Matinato C; Lunghi G; Torresani E; Ronchi M; Garlaschi MC; Ramondetta M; Colombo M
J Viral Hepat; 2014 Dec; 21(12):944-9. PubMed ID: 25040504
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α.
Keppeke GD; Nunes E; Ferraz ML; Silva EA; Granato C; Chan EK; Andrade LE
PLoS One; 2012; 7(9):e45392. PubMed ID: 23028980
[TBL] [Abstract][Full Text] [Related]
12. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.
Muratori P; Muratori L; Guidi M; Granito A; Susca M; Lenzi M; Bianchi FB
Clin Infect Dis; 2005 Feb; 40(4):501-7. PubMed ID: 15712070
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies against inosine-5'-monophosphate dehydrogenase 2--characteristics and prevalence in patients with HCV-infection.
Seelig HP; Appelhans H; Bauer O; Blüthner M; Hartung K; Schranz P; Schultze D; Seelig CA; Volkmann M
Clin Lab; 2011; 57(9-10):753-65. PubMed ID: 22029192
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
[TBL] [Abstract][Full Text] [Related]
19. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.
Yee HS; Currie SL; Tortorice K; Cozen M; Shen H; Chapman S; Cunningham F; Monto A
Dig Dis Sci; 2011 Aug; 56(8):2439-48. PubMed ID: 21633833
[TBL] [Abstract][Full Text] [Related]
20. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
